At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Sunitinib Malatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma
In Brief
A Phase 2 clinical trial evaluating Sunitinib Malate for Endometrial Adenocarcinoma and 7 related conditions. Completed, enrolled 34 participants across 29 sites in 2 countries.
Detailed Summary
This phase II trial studies how well sunitinib malate works in treating patients with endometrial cancer that has come back after a period of improvement (recurrent) or has spread to other places in the body (metastatic). Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Carcinosarcoma, Uterine Corpus Carcinosarcoma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2007
Primary CompletionFeb 2019
TodayJul 2026
First PostedMay 24, 2007
Enrollment StartApr 30, 2007
Primary CompletionFeb 12, 2019
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 19.1 years ago
Interventions
Sunitinib Malatedrug
Given PO